Aprea Therapeutics, Inc. (APRE)

$0.8511

-0.04 (-4.45%)
Rating:
Recommendation:
-
Symbol APRE
Price $0.8511
Beta 0.166
Volume Avg. 0.80M
Market Cap 19.917M
Shares () -
52 Week Range 0.62-5.67
1y Target Est -
DCF Unlevered APRE DCF ->
DCF Levered APRE LDCF ->
ROE -134426.05% Strong Sell
ROA -91470.18% Strong Sell
Operating Margin -
Debt / Equity -213.71% Sell
P/E -
P/B -0.54
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest APRE news


Mr. Christian S. Schade
Healthcare
Biotechnology
NASDAQ Global Select

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.